Cidara Therapeutics Inc
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are funga… Read more
Cidara Therapeutics Inc (CDTX) - Net Assets
Latest net assets as of September 2025: $422.39 Million USD
Based on the latest financial reports, Cidara Therapeutics Inc (CDTX) has net assets worth $422.39 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($518.65 Million) and total liabilities ($96.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $422.39 Million |
| % of Total Assets | 81.44% |
| Annual Growth Rate | N/A |
| 5-Year Change | 1424.11% |
| 10-Year Change | 57.16% |
| Growth Volatility | 156.6 |
Cidara Therapeutics Inc - Net Assets Trend (2013–2024)
This chart illustrates how Cidara Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cidara Therapeutics Inc (2013–2024)
The table below shows the annual net assets of Cidara Therapeutics Inc from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $163.31 Million | +2089.14% |
| 2023-12-31 | $-8.21 Million | +43.14% |
| 2022-12-31 | $-14.44 Million | -166.93% |
| 2021-12-31 | $21.57 Million | +101.33% |
| 2020-12-31 | $10.71 Million | -71.68% |
| 2019-12-31 | $37.84 Million | -36.02% |
| 2018-12-31 | $59.14 Million | -1.01% |
| 2017-12-31 | $59.74 Million | -32.25% |
| 2016-12-31 | $88.18 Million | -15.14% |
| 2015-12-31 | $103.91 Million | +392.40% |
| 2014-12-31 | $21.10 Million | +1609.51% |
| 2013-12-31 | $-1.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cidara Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 61119200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Components | $774.57 Million | 474.30% |
| Total Equity | $163.31 Million | 100.00% |
Cidara Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Cidara Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fortune Brands Innovations Inc.
NYSE:FBIN
|
$5.12 Billion |
|
ICICI Lombard General Insurance Company Limited
NSE:ICICIGI
|
$5.13 Billion |
|
Orica Limited
PINK:OCLDF
|
$5.13 Billion |
|
One Gas Inc
NYSE:OGS
|
$5.13 Billion |
|
Aurora Innovation Inc
NASDAQ:AUR
|
$5.11 Billion |
|
Elastic NV
NYSE:ESTC
|
$5.11 Billion |
|
Vibra Energia S.A.
SA:VBBR3
|
$5.11 Billion |
|
Chang Hwa Commercial Bank Ltd
TW:2801
|
$5.10 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cidara Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -8,210,000 to 163,308,000, a change of 171,518,000.
- Net loss of 169,827,000 reduced equity.
- New share issuances of 337,330,000 increased equity.
- Other factors increased equity by 4,015,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-169.83 Million | -103.99% |
| Share Issuances | $337.33 Million | +206.56% |
| Other Changes | $4.01 Million | +2.46% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Cidara Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.61x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-3.67 | $221.38 | x |
| 2013-12-31 | $-86.38 | $221.38 | x |
| 2014-12-31 | $514.80 | $221.38 | x |
| 2015-12-31 | $150.93 | $221.38 | x |
| 2016-12-31 | $121.72 | $221.38 | x |
| 2017-12-31 | $68.28 | $221.38 | x |
| 2018-12-31 | $45.72 | $221.38 | x |
| 2019-12-31 | $25.28 | $221.38 | x |
| 2020-12-31 | $5.16 | $221.38 | x |
| 2021-12-31 | $8.23 | $221.38 | x |
| 2022-12-31 | $-4.13 | $221.38 | x |
| 2023-12-31 | $-1.88 | $221.38 | x |
| 2024-12-31 | $25.72 | $221.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cidara Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -103.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -13319.76%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.32x
- Recent ROE (-103.99%) is above the historical average (-109.55%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-785.50K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.20 Million |
| 2014 | -56.36% | 0.00% | 0.00x | 1.15x | $-14.00 Million |
| 2015 | -30.98% | 0.00% | 0.00x | 1.06x | $-42.58 Million |
| 2016 | -54.62% | 0.00% | 0.00x | 1.21x | $-56.98 Million |
| 2017 | -93.28% | 0.00% | 0.00x | 1.32x | $-61.70 Million |
| 2018 | -99.79% | 0.00% | 0.00x | 1.34x | $-64.93 Million |
| 2019 | -108.61% | -196.47% | 0.30x | 1.82x | $-44.88 Million |
| 2020 | -672.99% | -597.59% | 0.20x | 5.64x | $-73.18 Million |
| 2021 | -203.54% | -88.58% | 0.66x | 3.49x | $-46.07 Million |
| 2022 | 0.00% | -46.35% | 1.35x | 0.00x | $-28.36 Million |
| 2023 | 0.00% | -98.49% | 0.35x | 0.00x | $-22.11 Million |
| 2024 | -103.99% | -13319.76% | 0.01x | 1.32x | $-186.16 Million |
Industry Comparison
This section compares Cidara Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cidara Therapeutics Inc (CDTX) | $422.39 Million | 0.00% | 0.23x | $5.12 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |